Dr. Lee Kaplan took the stage with an urgent message, telling fellow physicians they have a powerful weapon to fight the ...
As doctors in the United States scale back their prescription of opioid painkillers, a new option for hard-to-treat pain is taking root: ketamine, the decades-old surgical drug that is now a ...
Whether for weight loss or diabetes management, Canadian pharmacists say demand for Ozempic prescriptions does not appear to be slowing, despite a proposed lawsuit over alleged side effects.
Commissions we earn from partner links on this page do not affect our opinions or evaluations. Our editorial content is based on thorough research and guidance from the Forbes Health Advisory Board.
Britain prevents Ozempic reaching people who want to lose weight because of a national semaglutide shortage. But some pay ...
Prescriptions for semaglutide jumped 150% in the past year, with an 80% increase in prescriptions written per provider, new data suggest. Among more than 350,000 prescribers in the nationwide ...
Visit the MedPage Today Information Center to learn more about how you can contribute as a physician or other healthcare provider. Visit us on Facebook. Opens in a new tab or window Visit us on X.
Many pharmacists are uncertain about how to deal with pre-printed prescriptions: prescription pads preprinted with the drug name, quantity, and, less frequently, directions for use. Although these ...
It’s unusual for a medication to become a household name; even more uncommon for its branding to become, like Advil, shorthand for an entire class of products; and rarest of all, for it to ...
Trish Webster, 56, was prescribed Ozempic to help her squeeze into her dream dress for her daughter’s nuptials. Ozempic is a medication approved by the US Food and Drug Administration for people ...
Glen Patton says he's not one to panic. But a global shortage of the diabetes drug Ozempic has diabetics like him rattled — he says access to the medication could mean the difference between ...
Drugmakers Eli Lilly and Novo Nordisk both reported strong third-quarter sales growth Thursday, citing the performance of the GLP-1 class of diabetes and anti-obesity drugs that are in high demand.
